“TNFi, IL17i, JAKi--- note that these are the only classes of drug that work for axial spondyloarthritis!” – Dr. @AlexisOgdie noted ustekinumab, apremilast, and abatacept do not work for inflammatory back pain. @rheumnow #RLN2024 https://t.co/BHV6qCUdYi

#RNL2024 @RheumNow @AlexisOgdie Many therapies for SpA - but ONLY TNFi, IL17i, and JAKi for AxSpA Check out https://t.co/V7JGc6t72C to help guide treatment decisions: Prior therapies? enthesitis? concomitant IBD/uveitis? comorbidities? Pt preferences? https://t.co/hfFikMs9YL

Thinking of joint, skin, axial disease in psoriatic arthritis and extra-articular manifestations leading to shared decision making, Alexis Ogdie #RNL2024 @RheumNow https://t.co/F57sEicht7

Evolution of treatment landscape in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ut1e5Z2CjK

Cognitive framework for selecting therapy in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ZepkyA0mWj

@AlexisOgdie discusses the current and expected future SpA therapeutic options. However, and I also discuss this with my patients, we are more limited in AxSpA vs PsA (with axial disease.) #RNL2024 @RheumNow https://t.co/dlVgWblSXy

Importance of focusing on patient goals in psoriatic arthritis, use shared decision making and apply the clinical guidelines and treatment options within this context, Alexis Ogdie #RNL2024 @RheumNow https://t.co/jCFWUqJNn3

Functional outcomes of immune aging. Connie Weyand. #RNL2024 @RheumNow https://t.co/ZLL7N30n13

Clinical implications of immune aging. Connie Weyand. #RNL2024 @RheumNow https://t.co/QUbvkIvPco

Stressed ER is a major TNF producer. Connie Weyand. #RNL2024 @RheumNow https://t.co/zsSD8XWFcP

Consequence of aged immune system. Connie Weyand. #RNL2024 @RheumNow https://t.co/gfCTfzulR9

Remission in gout is 6 to 12 months with no flares. Lisa Stamp. #RNL2024 @RheumNow https://t.co/OlJK7HMNeX